Kexing Biopharm Balance Sheet Health
Financial Health criteria checks 3/6
Kexing Biopharm has a total shareholder equity of CN¥1.6B and total debt of CN¥1.2B, which brings its debt-to-equity ratio to 72.1%. Its total assets and total liabilities are CN¥3.1B and CN¥1.4B respectively.
Key information
72.1%
Debt to equity ratio
CN¥1.17b
Debt
Interest coverage ratio | n/a |
Cash | CN¥542.29m |
Equity | CN¥1.62b |
Total liabilities | CN¥1.44b |
Total assets | CN¥3.06b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 688136's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥766.6M).
Long Term Liabilities: 688136's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥673.4M).
Debt to Equity History and Analysis
Debt Level: 688136's net debt to equity ratio (38.7%) is considered satisfactory.
Reducing Debt: 688136's debt to equity ratio has increased from 25.3% to 72.1% over the past 5 years.
Debt Coverage: 688136's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 688136's interest payments on its debt are well covered by EBIT.